A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 22, 2016

Primary Completion Date

February 6, 2020

Study Completion Date

November 18, 2020

Conditions
Glioma
Interventions
RADIATION

High Dose Radiation

Radiation will be delivered once daily for a total of 30 fractions, five days per week.

DRUG

Temozolomide

Patients will receive concurrent temozolomide (75 mg/m\^2 daily for 6 weeks). Adjuvant temozolomide will be given at 150-200 mg/m\^2, D1-5 every 28 days for a minimum of six cycles and will be started approximately four weeks following completion of radiotherapy.

Trial Locations (1)

48109

University of Michigan Hospital, Ann Arbor

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER

NCT02805179 - A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma | Biotech Hunter | Biotech Hunter